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Abstract
It is known that physical linkage of TLR ligands and vaccine antigens significantly enhances the immunopotency of the
linked antigens. We have used this approach to generate novel influenza vaccines that fuse the globular head domain of the
protective hemagglutinin (HA) antigen with the potent TLR5 ligand, flagellin. These fusion proteins are efficiently expressed
in standard E. coli fermentation systems and the HA moiety can be faithfully refolded to take on the native conformation of
the globular head. In mouse models of influenza infection, the vaccines elicit robust antibody responses that mitigate
disease and protect mice from lethal challenge. These immunologically potent vaccines can be efficiently manufactured to
support pandemic response, pre-pandemic and seasonal vaccines.
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Introduction
Influenza is one of the major infectious disease threats to the
human population. It affects individuals of all ages, causes
repeated infections throughout life, and is responsible for recurrent
seasonal epidemics as well as periodic global pandemics of varying
severity. Vaccines are central both to the effective control of
seasonal outbreaks and to pandemic preparedness. Hemagglutinin
(HA) has been the key protective antigen in seasonal influenza
vaccines for the last forty years. While its structure and the basis of
its efficacy are well understood, the genetic variability of HA
coupled with current methods of vaccine production make it
exceedingly difficult to simultaneously meet seasonal and pan-
demic needs on a global basis. HA changes antigenically to evade
the immune response and on average, the prevalent influenza
strains in circulation will acquire three to four amino acid changes
per year in HA, mostly in regions of HA that are recognized by
protective antibodies. Mutations accumulate over time and
approximately every three to five years the virus evolves into an
antigenically distinct strain [1]. This requires regular updates of
the vaccine strains. Additionally, influenza vaccines are typically
produced in eggs via a process that takes place nearly year round.
Therefore, worldwide production capacity for influenza vaccines is
continuously dedicated to the production of seasonal vaccines
while pandemic preparedness, either in response to an emerging
pandemic or for the generation of a stockpile, requires the
redirection of manufacturing resources to the production of a
pandemic vaccine at the expense of the seasonal vaccine.
The current inter-related nature of seasonal and pandemic
vaccine production has led to intense interest in the development
of innovative technologies which could support both seasonal and
pandemic influenza vaccine production. Improvements in influ-
enza vaccine production by the industry have recently focused on
cell culture. This approach alleviates the significant manufacturing
issues associated with egg based manufacturing, but does not
improve production efficiency. The intense focus on cell culture
production stems from the historical view that protective forms of
HA antigens must be manufactured using eukaryotic cells, like
those of humans and chickens. The reason for this is that HA
undergoes host cell dependent post-translational modification and
even though the location and number of different glycosylation
sites are not conserved among HAs, it is thought that glycosylation
aids in correct folding of the molecule [2]. More recent data,
however, show that the glycosylation pattern of HA does not
impact the antibody response, suggesting that glycosylation is not
required for appropriate folding of the molecule [3].
In addition to improvements in vaccine production efficiency,
enhancement of the immunopotency of influenza vaccines will be
required in order to meet seasonal and pandemic needs on a
global scale. It is now well established that physical linkage of Toll-
like receptor (TLR) ligands and vaccine antigens enhances the
immunopotency of the linked antigen. TLRs are expressed on
various cell types, including professional antigen presenting cells
(APC), where they act as primary sensors of microbial infection
and then activate signaling pathways that lead to the induction of
immune and inflammatory genes. TLR agonists are molecules
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specifically associated with pathogenic organisms. Engagement of
TLRs by their cognate agonists and the subsequent signaling
within APC leads to enhanced processing and presentation of
antigens that are co-delivered to those APC [4,5]. Recently, we
demonstrated that the physical linkage of vaccine antigens to the
Toll-like receptor 5 (TLR5) ligand, flagellin, generates a
significantly more potent vaccine than simple mixing of antigen
and flagellin[6,7,8].
We here present an approach that addresses many of the
production and immunopotency barriers currently associated with
seasonal and pandemic influenza vaccines. We have identified a
single domain based on the globular head domain of HA which is
a self-sufficient protective subunit that can be produced using
prokaryotic expression systems. This globular head domain spans
the majority of the neutralizing epitopes in HA and stably refolds
to faithfully form these conformationally sensitive epitopes. We
have genetically fused the globular head subunit to the TLR5
ligand flagellin to create an immunologically potent, highly
protective vaccine that is very efficiently manufactured. The
increased production efficiency associated with these vaccines
means that they can be produced to meet national and even global
needs in a period of several months with minimal investments in
manufacturing infrastructure.
Results
Rational Design of Globular Head Constructs
Structural studies have shown that two polypeptides, HA1 and
HA2, form the monomeric subunit of the HA trimer. The HA1
polypeptide extends up from a membrane proximal stalk, spans
the globular head domain and then returns to the stalk. Based on
the architecture of HA1, we designed a subunit vaccine which
encompassed the neutralizing epitopes of the globular head and
also contained the structural elements necessary for spontaneous
and efficient folding to correctly display these epitopes after
recombinant protein expression in E.coli. The X-ray crystal
structure of A/Puerto Rico/8/34 (PR8) was used to guide the
design of three prototypic constructs [9] (Figure 1 A–C). In the
PR8 crystal structure the HA1 polypeptide has a long tail that
interacts with the central coiled-coil formed by the HA2 subunit.
The tail is loose and extended, a structural feature that could
complicate expression and refolding if included in a subunit
construct. By comparison, the globular head domain of HA1 is
compactly folded. The head is formed by multiple secondary
structural elements that include a b-pleated sheet on the top of the
head with tightly packed short a-helices underneath. A second,
three-stranded b-sheet lies underneath the a-helices on the
membrane-proximal side. An additional small b-sandwich is
situated underneath this second b-sheet. Non-structured peptides
connect the second b-sheet and the small b-sandwich. These
linking peptides do not function as stabilizing elements to the
tertiary structure of the globular head, and thus provide ideal sites
to truncate the globular head from the rest of HA1 such that it
folds independently. We hypothesized that interactions between
the a-helices and the second b-sheet, aided by a disulfide bond
between the third and fourth conserved cysteines of HA1, are the
minimal structural elements necessary for the stable, independent
folding of the head domain and maintenance of native,
neutralizing epitopes. Therefore, in the design of the first
prototypic construct, HA1-2, the boundary was placed in these
linking peptides at residues K62 on the N-terminus and S284 on
the C-terminus (Figure 1C). Two conserved disulfide bonds are
preserved in this molecule.
We also recognized that inclusion of the small b-sandwich could
be required to further stabilize the globular head domain subunit.
Figure 1. Depiction of the HA1-1, HA1-2 and HA1-3 globular head subunits. A) Ribbon diagram of the trimeric PR8 HA0 ectodomain with a
monomeric subunit of the HA trimer circled. B) Ribbon diagram of a monomer with the globular head circled. C) Ribbon diagram of the globular
head with the boundaries of the HA1-1, HA1-2 and HA1-3 constructs indicated by crosses. Each construct is presented in detail to the right. The
beginning and ending residue numbers, in PR8, for the three constructs are labeled. The important secondary structure elements, such as b-sandwich
in HA1-1 and the closing b-sheet in HA1-2 are also marked.
doi:10.1371/journal.pone.0002257.g001
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includes this additional secondary structure, and is similar to the
thermolysin released fragment previously described by Bizebard et
al [10]. The domain boundary for HA1-1 (PR8) was placed
between residues S53 and R324 (Figure 1C). The resulting
construct contains four conserved disulfide bonds.
In order to evaluate the importance of secondary structural
elements such as the second b-sheet and the small b-sandwich in
the stabilization of the independent head domain and the
consequent display of conformational epitopes, we designed a
third PR8 construct, HA1-3, as a control. The boundary for HA1-
3 (PR8) was placed at residues N101 to G276 to form a construct
which is similar in design and size to an HA subunit previously
reported by Jeon and Arnon [11]. The HA1-3 boundary
eliminates the b-sheet underneath HA1-2 and all but one
conserved disulfide bond.
Each of the globular head constructs were recombinantly linked
to the C terminus of Salmonella typhimurium type 2 flagellin (STF2)
and the resulting fusion proteins were designated as STF2.HA1-1
(PR8), STF2.HA1-2 (PR8) and STF2.HA1-3 (PR8) according to
their decreasing length.
Expression and Conformational Integrity of Flagellin
Fusion Proteins
The STF2.HA1-1 (PR8), STF2.HA1-2 (PR8) and STF2.HA1-3
(PR8) fusion proteins were expressed using standard E. coli cell
culture. All three proteins expressed equally well following
induction. Purified protein was denatured, refolded by rapid
dilution and analyzed by SDS-PAGE and western blot under
reducing and non-reducing conditions. The Coomassie stained
gels show that the purified STF2.HA1-2 (PR8) and STF2.HA1-3
(PR8) proteins were homogeneous. STF2.HA1-1 (PR8) had a
predominant band migrating at the correct size and a minor band
migrating at a higher apparent molecular weight (Figure 2A).
To evaluate the conformational integrity of the HA subunit of
the fusion proteins, Western blots of the SDS-PAGE gels were
probed with either the flagellin-specific monoclonal antibody,
6H11, which recognizes a linear epitope (Figure 2B) or
convalescent mouse sera raised following a low dose challenge of
mice with PR8 virus (Figure 2C). Reactivity of the convalescent
sera with protein run in the absence versus the presence of
reductant was used as a measure of conformational integrity of the
HA moiety. The results show that while 6H11 reacted equally well
with all proteins before and after the addition of reductant, the
PR8 convalescent serum reacted strongly with the non-reduced
forms of STF2.HA1-2 (PR8) but very weakly with the reduced
forms, indicating that the majority of epitopes recognized by HA-
specific antibodies in the convalescent anti-sera are conformational,
and reliant on disulfide bonding. The residual reactivity with the
convalescent sera following the addition of reductant is likely due to
the small portion of polyclonal antibodies that recognize linear
epitopes rather than conformational epitopes. These results
demonstrate that the globular head domain correctly refolds during
the refolding and purification of STF2.HA1-2 (PR8) protein. A
similar pattern of reactivity was observed for the major band of
STF2.HA1-1 (PR8). Interestingly, the minor, slower-migrating
STF2.HA1-1 band co-migrates with the reduced form of the protein
and reacts poorly with the convalescent sera, suggesting that this
band corresponds to misfolded protein. In contrast to STF2.HA1-1
and STF2.HA1-2, the convalescent sera reacted poorly with both
the non-reduced and reduced forms of STF2.HA1-3 (PR8),
indicating that the globular head domain in this recombinant
protein is misfolded under the conditions tested. This is consistent
with our hypothesis that secondary structures positioned near the
peptides linking the globular head domain to the stalk are likely
required to ensure stable refolding of the molecule.
To further evaluate the conformational integrity of the HA
moiety of the STF2.HA1-1 (PR8), STF2.HA1-2 (PR8) and
STF2.HA1-3 (PR8) fusion proteins, ELISA plates were coated
with serial dilutions of the full length HA (ecto-domain, HA0,
produced in Hi5 cells), PR8 virus and the fusion proteins. The
coated plates were probed with either naı ¨ve or convalescent mouse
sera (Figure 3). As expected, none of the proteins reacted with
naı ¨ve sera (data not shown). PR8 convalescent sera reacted with
PR8 virus and ecto-domain HA0 slightly better than STF2.HA1-1
and STF2.HA1-2 due to their additional epitopes. STF2.HA1-1
was equally antigenic as STF2.HA1-2 despite the minor
contamination of the slower migrating band. Consistent with the
western blot results shown in Figure 2C, STF2.HA1-3 demon-
strated the least reactivity with the convalescent sera.
An in vitro assay based on a cell line that expresses TLR5 and
secretes TNF-a in response to TLR signaling was used to assess the
functional integrity of the flagellin moiety. In this assay, all three
fusion proteins induced strong TNFa secretion, indicative of potent
TLR5 activity (EC50#10 ng/ml for each protein). The endotoxin
level for each protein was lessthan 0.05 EU/mgasme as u re dbyLA L
assay. These results demonstrate that the flagellin moiety remains
functional in the context of the fusion protein.
Taken together, the results confirm the importance of secondary
structure in the appropriate refolding of the HA globular head
domain. While both the STF2.HA1-1 and STF2.HA1-2 protein
fold properly, the STF2.HA1-2 recombinant protein folds more
efficiently under the conditions tested. The globular head
component of STF2.HA1-3 fails to fold efficiently.
Figure 2. STF2.HA1-1, STF2.HA1-2 and STF2.HA1-3 expression, purification and immmunoreactivity. STF2.HA1-1, STF2.HA1-2 and
STF2.HA1-3 proteins were expressed and purified. Refolded proteins were analyzed by SDS-PAGE and Western blot analyses. A) Coomassie stained
gel showing the proteins run in the presence (R) or absence (N) of reductant. Bands of the appropriate molecular weight were observed for each
construct. B) Western blot analyses using the anti-flagellin monoclonal antibody, 6H11. C) Western blot using PR8-specific immune sera raised
following a sub-clinical infection of mice with the PR8 virus.
doi:10.1371/journal.pone.0002257.g002
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The conformational integrity of defined antigenic regions of the
PR8 globular head was tested using a panel of monoclonal
antibodies known to be specific for neutralizing epitopes located in
the globular head [12,13]. ELISA plates were coated with either
PR8 virus or the fusion proteins STF2.HA1-1 (PR8), STF2.HA1-2
(PR8) or STF2.HA1-3 (PR8). Plates were probed with neutralizing
monoclonal antibodies representing each of four previously
defined antigenic regions of PR8 (Sa, Sb, Ca, Cb, Figure 4A).
As shown in Figure 4B-4E the STF2.HA1-1 (PR8), STF2.HA1-2
(PR8) proteins and the influenza virus reacted comparably with
the panel of monoclonal antibodies. There is some reduction in
reactivity for the STF2.HA1-1 (PR8) protein which is likely due to
the presence of misfolded molecules in the preparation, in
agreement with the western blot and convalescent serum ELISA
data presented above. The STF2.HA1-3 (PR8) protein failed to
bind the monoclonal antibodies.
The structural integrity of these neutralizing epitopes was
further examined using competition assays. Since the panel of
monoclonal antibodies reacted equally well with plate-bound
STF2.HA1-2 (PR8) and virus particles, the ELISA plates were
coated with the STF2.HA1-2 (PR8) fusion protein. The panel of
monoclonal antibodies was incubated with the HA1-2 globular
head protein alone, STF2.HA1-2 or STF2.HA1-3 for 2 hours.
HA1-1 globular head alone or the STF2.HA1-1 protein produced
in baculovirus (HA1-1 bv) were included in the evaluation. The
mixture was transferred to the ELISA plates and the specific
monoclonal antibody reactivity was measured following washing
and blocking of the plates. The results (Figure 4F–I) show that
HA1-1bv, STF2.HA1-1bv, HA1-2, and STF2.HA1-2, but not
STF2.HA1-3 proteins compete for binding of the monoclonal
antibodies to plate-bound STF2.HA1-2. These results demon-
strate that HA1-1 and HA1-2, either in the context of the fusion or
expressed alone, fold properly and that the neutralizing epitopes
are correctly displayed. The results further confirm that the
STF2.HA1-3 protein fails to stably refold.
Immunogenicity and Efficacy of STF2.HA1-2 in Mice
Groups of 10 BALB/c mice were immunized on days 0 and 14
with 3, 0.3 and 0.03 mg of STF2.HA1-2. A group of naı ¨ve mice
was included as a negative control. On day 10, animals were bled
and the sera of individual animals examined for HA-specific IgG
by probing ELISA plates coated with the PR8 virus (Figure 5A).
Pooled convalescent sera were included as a positive control. The
results demonstrate that immunization with as little as 0.03 mgo f
STF2.HA1-2 induced measurable levels of HA-specific antibodies
post the priming immunization. Mice were subsequently chal-
lenged on day 28 with 16LD90 of the mouse-adapted influenza
PR8 virus delivered intranasally. Survival and weight loss were
followed for 21 days (Figure 5B and C). As shown in Figure 5B,
naı ¨ve mice exhibited signs of infection as early as 4 days post-
challenge and 90% of the animals succumbed to the lethal
challenge by day 21. In contrast, 100% of mice immunized with
3 mg of STF2.HA1-2 (PR8) and 90% of mice immunized with
0.3 mg of STF2.HA1-2 (PR8) survived the challenge. Mice
immunized with 3 mg of STF2.HA1-2 (PR8) exhibited no signs
of disease as measured by weight loss while mice immunized with
as little as 0.3 mg exhibited only very mild weight loss (Figure 5C).
Forty percent of mice immunized with 0.03 mg were protected
against the lethal challenge. These results demonstrate that E. coli
expressed STF2.HA1-2 induces an HA-specific immune response
that successfully protects BALB/c mice from a lethal challenge
with influenza A virus.
Application to a Currently Circulating Influenza A Strain
The same principles of design were applied to the HA of the
currently circulating seasonal strain A/Solomon Islands/3/2006
(SI). Protein was expressed and purified using the methodologies as
for the prototypic PR8 construct. To evaluate the immunogenicity
and efficacy of this construct, groups of 10 BALB/c mice were
immunized on day 0 and day 14 with 3 or 0.3 mg of STF2.HA1-2
(SI), and bled on day 21. Sera were analyzed for hemagglutination
inhibition of SI virus using chicken red blood cells as the target.
Geometric mean titers (GMT) were 1:320 (range 1:160–1:640) at
the 3 mg dose level and 1:226 (range 1:80–1:640) at the 0.3 mg
dose level. Ferret immune sera, raised on natural infection and
obtained from CDC, exhibited an HAI titer of 1:320. To further
characterize the potency of the vaccine, 15 BALB/c mice were
immunized twice with 10, 1 or 0.1 mg of STF2.HA1-2 (SI). Sera
were harvested 1 week post the boosting immunization and
evaluated for microneutralization titers. In instances where a
mouse adapted strain of the virus is not available, as is the case for
this seasonal strain, neutralization titers of $1:40 are generally
accepted as a correlate of efficacy. The results are reported as
GMT in Table 1. The results show that doses of 1 mg elicit GMT
titers well above 1:40 in the mouse model.
To further evaluate the immunopotency of STF2.HA1-2 (SI),
groups of 6 New Zealand White rabbits were immunized twice,
i.m., with 15 or 5 mg of STF2.HA1-2 (SI). Sera were harvested 3
weeks post the boosting immunization and tested for microneu-
tralization titers. The results in Table 1 demonstrate that
STF2.HA1-2 (SI) elicits robust virus neutralizing titers in the
rabbit model. Ferret immune sera, raised on natural infection and
obtained from the CDC, was included as a positive control in these
assays and found to have a neutralizing titer of 1:5,120.
Discussion
We have identified the structural elements necessary for efficient
refolding of a protective HA subunit after recombinant protein
expression in E.coli. Structural information is available for the H1
Figure 3. Immunoreactivity of STF2.HA1-1, STF2.HA1-2 and
STF2.HA1-3 in ELISA. ELISA plates were coated with the 0.2 mg/well
of indicated STF2 fusion proteins, PR8 virus or the full length PR8 HA0
ectodomain expressed in Hi5 cells. Plates were probed with either naı ¨ve
or PR8 convalescent sera at indicated dilution. Following incubation
with HRP-conjugated goat anti-mouse IgG, plates were developed with
UltraTMB substrate. Results reflect the delta value of OD450 (Convales-
cence-Naı ¨ve) of samples performed in duplicate. Naı ¨ve values (data not
shown) were below 0.02.
doi:10.1371/journal.pone.0002257.g003
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PLoS ONE | www.plosone.org 4 May 2008 | Volume 3 | Issue 5 | e2257Figure 4. Comparative recognition of STF2.HA1-1, STF2.HA1-2, STF2.HA1-3 and PR8 virus by neutralizing monoclonal antibodies.
A) Ribbon diagram depicting of the known antigenic regions of the HA globular head. B–E) ELISA plates were coated with either PR8 virus or the
STF2 fusion proteins and probed with a mAb specific for the Sb, Sa, Ca1, Ca2 and Cb region. All STF2 fusion proteins are produced from E coli. F–I)
ELISA plates were coated with STF2.HA1-2 and competed against soluble form of HA1-1, HA1-2, STF2.HA1-2, STF2.HA1-3 in binding of the panel of
monoclonal antibodies (H37-64, 18 ng/ml; H37-77, 8 ng/ml; H36-11, 188 ng/ml and H163, 500 ng/ml). Bound antibodies were detected by 450 nm
absorption. HA1-1 and STF2.HA1-1 were produced in insect cell culture. Both proteins have C-terminal 6His tag. HA1-2, STF2.HA1-2 and STF2.HA1-3
were produced in E. coli. HA1-2 has 6His tag at C-terminus.
doi:10.1371/journal.pone.0002257.g004
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well as for an influenza C HEF (hemagglutinin, esterase, and
fusion glycoprotein) [17]. Comparisons of these structures show
that the different HAs, while antigenically distinct, are structurally
similar and share a common sub-domain organization. Each HA
monomer folds to form a membrane proximal stalk and a
membrane distal globular head domain. The globular head stands
independently from the central stalk and contains the majority of
the neutralizing antibody epitopes [12,13]. We designed three PR8
HA prototypic constructs to test the hypothesis that secondary
structures such as the b-pleated sheets near these linker peptides
are sufficient to support the head domain as a self-stabilizing unit
that can be engineered and expressed apart from the rest of the
molecule.
We find that of the three prototypic constructs evaluated,
STF2.HA1-2 provides the level of expression and ease of
conformationally correct refolding required to support a truly
efficient, scalable manufacturing process. This molecule expressed
well in our prokaryotic system and refolded easily using rapid
dilution. STF2.HA1-1 also refolded albeit with somewhat lower
efficiency than STF2.HA1-2, presumably as a consequence of the
additional domain and two additional disulfide bonds. Western blots
of STF2.HA1-1 run under reducing and non-reducing conditions
and probed with PR8 convalescent sera reveal a band in the non-
reduced sample that co-migrates with the main band in the reduced
sample suggesting that a significant proportion of the protein
remained misfolded. STF2.HA1-3 refolded the least efficiently, most
likely due to the absence of secondary structures required for stable
refolding.Reactivitywith a panelof defined neutralizing monoclonal
antibodies further supports this conclusion.
STF2.HA1-2 (PR8) was found to be highly immunogenic and
efficacious against a lethal challenge in the mouse model. Mice
receiving doses of STF2.HA1-2 (PR8) as low as 0.3 mgw e r e
protected against a lethal challenge of virus. These data demonstrate
that a subunit of HA based on the globular head domain can be fully
protective in a standard mouse lethal challenge model. When the
same principles of design were applied to the currently circulating
seasonal strain, A/Solomon Islands/3/2006, we found that
STF2.HA1-2 (SI) was highly immunogenic in both mice and
rabbits. In mice doses of 1 mg elicited geometric mean neutralizing
titers of 1:297 and in rabbits doses of 5 mg elicited titers of 1:453.
Thus, the principles of design for these protective subunit vaccines
can be applied to different HA molecules.
A key benefit with this approach is that the STF2.HA1-2
recombinant fusion protein can be made quickly, inexpensively
and in quantities sufficient to meet global needs. The efficiency of
this technology translates approximately into a 1,000 fold gain in
production. As a point of reference, the average yield for cell
culture is 3 mg/L; for egg based production, 7 mg/L; for
baculovirus recombinant synthetic protein, 13 mg/L and for the
standard prokaryotic system described here, 3,700 mg/L. This
increase in production capacity, along with the fact that it is
Figure 5. STF2.HA1-2 mediated protective immunity against
lethal challenge in vivo. BALB/c mice (10/group) were immunized on
day 0 and 14 with 3, 0.3 or 0.03 mg of STF2.HA1-2. A group receiving
formulation buffer alone was included as a negative control. A) Sera
were harvested on day 21 and evaluated for HA-specific antibody
responses by ELISA. B–C) On day 28, mice were challenged i.n. with
16LD90 of influenza PR8. Survival (B) and weight loss (C) of individual
mice were monitored for 21 days post-challenge.
doi:10.1371/journal.pone.0002257.g005
Table 1. Neutralization of Influenza A/Solomon Islands/3/06
by Mouse and Rabbit Immune Sera
Groups [N] Dose
a GMT
b 95% CI
c
Mouse
STF2.HA1-2 (SI) [10] 10 845
*** 472–1511
STF2.HA1-2 (SI) [14] 1 297
*** 106–833
STF2.HA1-2 (SI) [10] 0.1 8 4–20
Naive 5 5–5
Rabbit
STF2.HA1-2 (SI) [6] 15 640
*** 404–1014
STF2.HA1-2 (SI) [6] 5 453
*** 211–971
Naı ¨ve [6] 40 40–40
amg/animal;
bgeometric mean titers;
c95% confidence intervals;
***, p,0.001, significance vs naı ¨ve in ANOVA/Tukey Multiple Comparison Test.
doi:10.1371/journal.pone.0002257.t001
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address several shortcomings of the current egg-based system. One
advantage deriving from increased capacity is the ability to
increase the dose of antigen. Studies have shown that persons
greater than 65 years of age respond less well to the standard
vaccine, and that increasing the dose of HA four to five-fold
substantially improves the immune response in this segment of the
population. Formulation of a ‘‘high-dose’’ vaccine for the elderly
becomes a practical possibility with an unconstrained supply of
antigen. A second set of advantages comes from eliminating the
growth of virus from the manufacturing process. Currently,
vaccine production strains are created by crossing the HA and
NA genes from candidate circulating strains onto an egg-adapted
virus, generally the PR/8/34 strain. Manufacturers then further
adapt these production strains to create high-yield viruses. The
adaptation process results in selection of mutations in the upper
part of the HA globular head near the receptor binding site [18].
As a consequence, the HA in the vaccine may be different from
the HA in the original viral isolate. Prokaryotic expression, based
on a cDNA copy of the original isolate HA, avoids genetic
selection during the production process. In addition, there are
situations where a suitable production strain cannot be created by
conventional methods. In these cases, a related HA production
strain is pressed into service. Eliminating the need to grow virus
allows the production of the desired antigen with the original
sequence.
In conclusion, the manufacturing approach described herein
has major advantages over existing technologies in that it allows
faster molecular development, rapid manufacturing and very high
levels of productivity at small manufacturing scales. These
advantages are critical to the successful production of seasonal
and pandemic influenza vaccines.
Materials and Methods
Cloning of recombinant HA genes
E. coli. The codon optimized synthetic genes of the
hemagglutinin (HA) globular head domain of PR8 were fused to
the C-terminus of the full-length sequence of Salmonella typhimurium
fljB (flagellin phase 2), STF2 (DNA2.0 Inc., Menlo Park, CA). The
sequence SGSGSGS was incorporated at the junction of STF2
and HA as a flexible linker. The resulting fragments corresponding
to the STF2.HA1-1, 1-2 and 1-3 genes respectively were cloned to
pET24a vector to generate the constructs STF2.HA1-1,
STF2.HA1-2 and STF2.HA1-3. The proteins were expressed in
BLR3 (DE3) cells (Novagen, San Diego, CA; Cat #69053).
Baculovirus. The synthetic genes encoding HA1-1 (PR8) or in
fusion with STF2 were codon-optimized for Baculovirus expression
(DNA2.0 Inc., Menlo Park, CA) and cloned into pFastBac
TM.T h e
honey bee mellitin sequence (MKFLVNVALVFMVVYISYIYAD
PS) was fused to the amino terminus of recombinant proteins to
provide a secretion signal and hexahistidine was tagged to the
carboxyl terminus to facilitate purification. The synthetic genes were
cloned to the pFastbac1 vector. The recombinant Baculovirus
generation followed standard Bac-to-BacH Baculovirus Expression
protocol (Invitrogen, Carlsbard, CA).
Protein production
High expresser clones were cultured overnight and used to
inoculate fresh LB medium supplemented with 25 mg/ml
kanamycin, 12.5 mg/ml tetracycline and 0.5% glucose. At an
OD600=0.6 protein expression was induced with 1 mM IPTG for
3 h at 37uC. Cells were harvested by centrifugation (8,000g for
7 minutes) and disrupted by microfluidizer (18,000 psi). The
inclusion body was washed with 1% Triton X100 and dissolved in
8 M urea. The filtered protein solution in 25 mM NaCl and
50 mM Acetate, pH 4.0 was applied to a SP Sepharose Fast Flow
column (GE/Amersham). The fraction peak was eluted by salt
gradient and buffer exchanged to 50 mM Tris, 25 mM NaCl and
8 M urea, pH 8.0. Protein refolding was achieved by rapid
dilution (1:10) into 100 mM Tris-HCl buffer (pH 8.0), and further
purified by anion exchange (Source Q, GE/Amersham). For final
polishing and endotoxin removal, a Superdex 200 gel filtration
column (10/300 GL, GE/Amersham) was used. The protein peak
was eluted using 100 mM Tris, 150 mM NaCl, 1% glycerol and
1% Na-deoxycholate elution buffer. Peak fractions were pooled,
dialyzed against 16PBS and stored at 280uC. For all 6xHis
tagged proteins, the metal chelating column was employed.
Protein was loaded to a Ni-NTA column equilibrated in 20 mM
Tris, pH 8, 0.5 M NaCl and eluted in a gradient of 0–0.5 M
imidazole. The target protein was further purified by size
exclusion column (10/300 GL, GE/Amersham). The peak
fractions were pooled, concentrated and dialyzed against
16PBS. Aliqoted protein solution was stored at 280uC.
Endotoxin contamination was assayed by using standard Chro-
mogenic Limulus Amebocyte Lysate assay (Cambrex, Walkers-
ville, MD) as directed by the manufacturer.
ELISAs
Many aspects of the ELISA methods were held in common.
ELISA plates were coated with the indicated proteins in PBS
overnight at 4uC or one hour at room temperature. All washes
between reagent addition steps were performed 3 times with 1X
PBS/0.05% Tween-20. Plates were blocked with 200–300 ml/well
of Assay Diluent Buffer (ADB; BD Pharmingen) for 1–3 hour at
23–27uC. After incubation with the indicated detection antibodies,
HRP-labeled goat anti-mouse antibody (Jackson Immunochemi-
cal) diluted in ADB was added and the plates were incubated at
23–27uC for 1 hour. After adding TMB Ultra substrate (Pierce)
and monitoring color development, the reaction was stopped with
1M H 2SO4 and OD450 was measured on a microplate
spectrophotometer.
Protein ELISAs. Plates were coated with serial dilutions of
proteins. After block, plates were probed with monoclonal
antibody specific for flagellin (6H11; Inotek) or convalescent sera
against PR8 virus overnight at 4uC.
Serum antibody determination. Plates were coated with
100 ml/well HA1-1 produced in insect cells in PBS (5 mg/ml).
Dilutions of the sera in ADB were added (100 ml/well) and the
plates were incubated overnight at 4uC.
Viral ELISA. Sucrose density gradient purified PR8 virus
(Advanced Biotechnologies Inc.,) or STF2 tagged recombinant
HA proteins were diluted to 4 mg/ml in 1X PBS and 100 ml
coated in triplicates. After block, plates were incubated with 100 ml
of HA-specific antibodies diluted in ADB at 25uC for 2.5 hours.
Competition ELISA. Plates were coated overnight with
100 ml/well STF2.HA1-2 (PR8) at 2 mg/ml. Antibodies were
pre-incubated with serially diluted recombinant proteins for
2 hours at 25uC and added to the washed and blocked
STF2.HA1-2 (PR8) coated plates for a further 2 hour incubation
followed by detection antibody. The amount of antibody used for
each epitope was pre-determined to be in the linear range of a
saturation curve in ELISA.
Cells and viruses
MDCK cells were obtained from ATCC and maintained in
DMEM supplemented with 5% FBS, 2 mM L-glutamine, 100
units/ml Penicillin and 100 mg/ml Streptomycin. Influenza
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2006, were obtained from Dr. Y. Kawaoka (University of
Wisconsin) and CDC, respectively, and propagated in either
MDCK cells or 11-day old SPF embryonated hen’s eggs (Charles
River Laboratories, North Franklin, CT).
TLR5 bioassay
The bioactivity of purified recombinant proteins was tested as
previously described [6].
Animal studies
BALB/c mice 6–8 weeks old were purchased from the Jackson
Laboratory (Bar Harbor, ME) and housed in either the Yale
University vivarium (New Haven, CT) or the Princeton University
vivarium (Princeton, NJ). All studies were performed in accor-
dance with the University Institutional Animal Care and Use
Committees (IACUC). Recombinant proteins were prepared in
one of two vehicles: PBS (phosphate-buffered saline) or formula
F147 (10 mM L-histidine, 150 mM NaCl, 5% trehalose, 0.02%
polysorbate 80, 0.1 mM EDTA, 0.5% ethanol, 10 mM Tris,
pH 7.2). Vehicles were used interchangeably without detectable
impact on the results. Mice were immunized subcutaneously (s.c.)
on days 0 and 14. On days 13 (primary) and 21 (boost), individual
mice were bled by retro-orbital puncture. Sera were harvested by
clotting and centrifugation of the heparin-free blood samples.
Studies with female and male New Zealand White rabbits were
performed at Covance Research Products (Denver, PA). Rabbits (6/
group) were immunized intramuscularly (i.m.) on days 0 and 21 with
5o r1 5mg of STF2.HA1-2. Sera were harvested 3 weeks post the
booster and evaluated for HA-specific microneutalization titers.
Microneutralization assays
Serum samples were treated with receptor destroying enzyme II
(RDE, Denka Seiken Co., Ltd., Tokyo, Japan) and co-cultivated
with 100 TCID50 of influenza virus A/PR/8/34 or A/Solomon
Islands/3/2006 for 1.5 hr in series dilution (duplicate). MDCK
cells (4610
4 /well) in DMEM supplemented with 1% BSA,
20 mM HEPES, and 100 IU/ml Penicillin and 100 mg/ml
Streptomycin were then added and incubated for 20 hours at
37uC. Cells were washed, fixed, air-dried and incubated with a
monoclonal anti-influenza A nucleoprotein antibody (1:2,000,
clones A1 and A3, ATCC/BEI resources). Signals were detected
by OD450. Virus back titration, positive serum control, virus
controls (VC), and cell controls (CC) were included in the assay.
The end point of virus neutralizing antibody for each serum was
determined using 50% of specific signal=[(Average OD of VC
wells)–(Average OD of CC wells)]/2+Average OD of CC wells.
Values below this value are considered positive for neutralizing
activity.
Statistical analyses
The titers of neutralizing antibodies were transformed into
natural logarithm, and subjected to ANOVA/Tukey tests.
Survival curves between different groups were compared with
Log-rank test. Data analysis used GraphPad Prism version 5.00 for
Windows (GraphPad Software, San Diego California USA, www.
graphpad.com).
Influenza virus challenge of mice
To assess efficacy, mice immunized on days 0 and 14 as
described above were challenged on day 35 by intranasal
administration of 16LD90 (dose lethal to 90% of mice; 1610
3
TCID50) of influenza A isolate, PR8. Animals were monitored
daily for 21 days following the challenge for survival and weight
loss.
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